NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference
November 03 2021 - 4:15PM
Business Wire
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the
‘‘Company’’), a late-clinical stage biotechnology
company pioneering physics-based approaches to expand treatment
possibilities for patients with cancer, today announced that
Laurent Levy, Chief Executive Officer, will participate in a
fireside chat at the Jefferies London Healthcare Conference at 3:40
PM GMT / 10:40 AM EST on Tuesday, November 16, 2021.
The fireside chat will be webcast live from the Events section
of the company’s website at www.nanobiotix.com. A replay of the
webcast will be archived and available for one month following the
event.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company
pioneering disruptive, physics-based therapeutic approaches to
revolutionize treatment outcomes for millions of patients;
supported by people committed to making a difference for humanity.
The company’s philosophy is rooted in the concept of pushing past
the boundaries of what is known to expand possibilities for human
life. Incorporated in 2003, Nanobiotix is headquartered in Paris,
France. The company also has subsidiaries in Cambridge,
Massachusetts (United States), France, Spain, and Germany.
Nanobiotix has been listed on the regulated market of Euronext in
Paris since 2012 and on the Nasdaq Global Select Market in New York
City since December 2020. Nanobiotix is the owner of more than 30
umbrella patents associated with three (3) nanotechnology platforms
with applications in 1) oncology; 2) bioavailability and
biodistribution; and 3) disorders of the central nervous system.
The company's resources are primarily devoted to the development of
its lead product candidate– NBTXR3 —which is the product of its
proprietary oncology platform and has already achieved market
authorization in Europe for the treatment of patients with soft
tissue sarcoma under the brand name Hensify®. For more information
about Nanobiotix, visit us at www.nanobiotix.com or follow us on
LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211103006193/en/
Nanobiotix Communications Department Brandon Owens VP,
Communications +1 (617) 852-4835 contact@nanobiotix.com Investor
Relations Department Kate McNeil SVP, Investor Relations +1
(609) 678-7388 investors@nanobiotix.com Media Relations France –
Ulysse Communication Pierre-Louis Germain + 33 (0) 6 64 79
97 51 plgermain@ulysse-communication.com US – Porter Novelli
Dan Childs +1 (781) 888-5106 Dan.childs@porternovelli.com
Nanobiotix (EU:NANO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From Apr 2023 to Apr 2024